{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:55:08Z","timestamp":1793746508128,"version":"4.6.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Primary sclerosing cholangitis (PSC) is a liver disease known for its frequent concurrence with inflammatory bowel disease. Dysbiosis of the gut microbiota in PSC was reported in several studies, but the microbiological features of the salivary microbiota in PSC have not been established. Here we compared the salivary microbial communities of 24 pediatric-onset PSC patients, 16 age-matched ulcerative colitis (UC) patients, and 24 healthy controls (HCs) by analyzing the bacterial 16S rRNA gene sequence data. The species-richness (\u03b1-diversity) showed no significant between-group differences, whereas the overall salivary microbiota structure (\u03b2-diversity) showed significant differences among the three groups. Taxonomic assignment revealed that the PSC salivary microbiota were characterized by significant decreases in the abundance of <jats:italic>Rothia<\/jats:italic> and <jats:italic>Haemophilus<\/jats:italic> compared to the HC group, and significantly decreased <jats:italic>Haemophilus<\/jats:italic> and increased <jats:italic>Oribacterium<\/jats:italic> compared to the UC group. By combining the genera selected by the random forest algorithm in machine learning, followed by confirmation with 10-fold cross-validation, we were able to distinguish the PSC group from the HC group with the area under the curve (AUC) of 0.7423, and from the UC group with the AUC of 0.8756. Our results indicate the potential of salivary microbiota as biomarkers for a noninvasive diagnosis of PSC.<\/jats:p>","DOI":"10.1038\/s41598-018-23870-w","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T02:26:16Z","timestamp":1522290376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Dysbiosis of the salivary microbiota in pediatric-onset primary sclerosing cholangitis and its potential as a biomarker"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5387-0099","authenticated-orcid":false,"given":"Kentaro","family":"Iwasawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Tsunoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manari","family":"Oikawa-Kawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichiro","family":"Umetsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Takayasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayano","family":"Inui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoo","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Sogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahira","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,3]]},"reference":[{"key":"23870_CR1","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1056\/NEJMra1506330","volume":"375","author":"KN Lazaridis","year":"2016","unstructured":"Lazaridis, K. N. & LaRusso, N. F. Primary sclerosing cholangitis. N Engl J Med 375, 1161\u20131170 (2016).","journal-title":"N Engl J Med"},{"key":"23870_CR2","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1136\/gutjnl-2016-312533","volume":"66","author":"K Iwasawa","year":"2017","unstructured":"Iwasawa, K. et al. Characterisation of the faecal microbiota in Japanese patients with paediatric-onset primary sclerosing cholangitis. Gut 66, 1344\u20131346 (2017).","journal-title":"Gut"},{"key":"23870_CR3","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1053\/jhep.2003.50289","volume":"38","author":"AE Feldstein","year":"2003","unstructured":"Feldstein, A. E. et al. Primary sclerosing cholangitis in children: A long-term follow-up study. Hepatology 38, 210\u2013217 (2003).","journal-title":"Hepatology"},{"key":"23870_CR4","doi-asserted-by":"publisher","unstructured":"Deneau, M. R. et al. The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration. Hepatology, https:\/\/doi.org\/10.1002\/hep.29204 (2017).","DOI":"10.1002\/hep.29204"},{"key":"23870_CR5","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1053\/j.gastro.2016.06.021","volume":"151","author":"AK Lunder","year":"2016","unstructured":"Lunder, A. K. et al. Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease. Gastroenterology 151, 660\u2013669 e664 (2016).","journal-title":"Gastroenterology"},{"key":"23870_CR6","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/MPG.0b013e31825bb3dc","volume":"55","author":"E Alexopoulou","year":"2012","unstructured":"Alexopoulou, E. et al. Investigative MRI cholangiopancreatography for primary sclerosing cholangitis-type lesions in children with IBD. J Pediatr Gastroenterol Nutr 55, 308\u2013313 (2012).","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"23870_CR7","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/hep.23294","volume":"51","author":"R Chapman","year":"2010","unstructured":"Chapman, R. et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 51, 660\u2013678 (2010).","journal-title":"Hepatology"},{"key":"23870_CR8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00247-001-0617-z","volume":"32","author":"C Ferrara","year":"2002","unstructured":"Ferrara, C., Valeri, G., Salvolini, L. & Giovagnoni, A. Magnetic resonance cholangiopancreatography in primary sclerosing cholangitis in children. Pediatr Radiol 32, 413\u2013417 (2002).","journal-title":"Pediatr Radiol"},{"key":"23870_CR9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.clinre.2013.05.014","volume":"37","author":"G Rossi","year":"2013","unstructured":"Rossi, G. et al. Diagnosis of sclerosing cholangitis in children: Blinded, comparative study of magnetic resonance versus endoscopic cholangiography. Clin Res Hepatol Gastroenterol 37, 596\u2013601 (2013).","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"23870_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/MPG.0b013e31816fee95","volume":"47","author":"YK Davies","year":"2008","unstructured":"Davies, Y. K. et al. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: An immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 47, 61\u201367 (2008).","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"23870_CR11","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/hep.20457","volume":"40","author":"M Farkkila","year":"2004","unstructured":"Farkkila, M. et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: A randomized placebo-controlled trial. Hepatology 40, 1379\u20131386 (2004).","journal-title":"Hepatology"},{"key":"23870_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/ajg.2008.14","volume":"104","author":"MG Silveira","year":"2009","unstructured":"Silveira, M. G. et al. Minocycline in the treatment of patients with primary sclerosing cholangitis: Results of a pilot study. Am J Gastroenterol 104, 83\u201388 (2009).","journal-title":"Am J Gastroenterol"},{"key":"23870_CR13","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/apt.12232","volume":"37","author":"JH Tabibian","year":"2013","unstructured":"Tabibian, J. H. et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis \u2014 A pilot study. Aliment Pharmacol Ther 37, 604\u2013612 (2013).","journal-title":"Aliment Pharmacol Ther"},{"key":"23870_CR14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","volume":"25","author":"S Rahimpour","year":"2016","unstructured":"Rahimpour, S. et al. A Triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: A pilot study. J Gastrointestin Liver Dis 25, 457\u2013464 (2016).","journal-title":"J Gastrointestin Liver Dis"},{"key":"23870_CR15","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/ecco-jcc\/jju023","volume":"9","author":"NG Rossen","year":"2015","unstructured":"Rossen, N. G. et al. The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II. J Crohns Colitis 9, 342\u2013348 (2015).","journal-title":"J Crohns Colitis"},{"key":"23870_CR16","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/ecco-jcc\/jjv204","volume":"10","author":"D Kevans","year":"2016","unstructured":"Kevans, D. et al. Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis. J Crohns Colitis 10, 330\u2013337 (2016).","journal-title":"J Crohns Colitis"},{"key":"23870_CR17","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/apt.13552","volume":"43","author":"J Torres","year":"2016","unstructured":"Torres, J. et al. The features of mucosa-associated microbiota in primary sclerosing cholangitis. Aliment Pharmacol Ther 43, 790\u2013801 (2016).","journal-title":"Aliment Pharmacol Ther"},{"key":"23870_CR18","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1136\/gutjnl-2016-311915","volume":"66","author":"MN Quraishi","year":"2017","unstructured":"Quraishi, M. N. et al. The gut-adherent microbiota of PSC-IBD is distinct to that of IBD. Gut 66, 386\u2013388 (2017).","journal-title":"Gut"},{"key":"23870_CR19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1136\/gutjnl-2015-310500","volume":"66","author":"M Kummen","year":"2017","unstructured":"Kummen, M. et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut 66, 611\u2013619 (2017).","journal-title":"Gut"},{"key":"23870_CR20","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1136\/gutjnl-2015-311004","volume":"65","author":"J Sabino","year":"2016","unstructured":"Sabino, J. et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut 65, 1681\u20131689 (2016).","journal-title":"Gut"},{"key":"23870_CR21","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1136\/gutjnl-2016-312180","volume":"66","author":"MC Ruhlemann","year":"2017","unstructured":"Ruhlemann, M. C. et al. Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis. Gut 66, 753\u2013754 (2017).","journal-title":"Gut"},{"key":"23870_CR22","doi-asserted-by":"publisher","unstructured":"Torres, J. et al. The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease. United European Gastroenterol J, 205064061770895, https:\/\/doi.org\/10.1177\/2050640617708953 (2017).","DOI":"10.1177\/2050640617708953"},{"key":"23870_CR23","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.3748\/wjg.v23.i25.4548","volume":"23","author":"L Bajer","year":"2017","unstructured":"Bajer, L. et al. Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis. World J Gastroenterol 23, 4548\u20134558 (2017).","journal-title":"World J Gastroenterol"},{"key":"23870_CR24","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.cell.2012.01.035","volume":"148","author":"JC Clemente","year":"2012","unstructured":"Clemente, J. C., Ursell, L. K., Parfrey, L. W. & Knight, R. The impact of the gut microbiota on human health: An integrative view. Cell 148, 1258\u20131270 (2012).","journal-title":"Cell"},{"key":"23870_CR25","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1002\/hep.27819","volume":"62","author":"JS Bajaj","year":"2015","unstructured":"Bajaj, J. S. et al. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology 62, 1260\u20131271 (2015).","journal-title":"Hepatology"},{"key":"23870_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/dnares\/dst037","volume":"21","author":"HS Said","year":"2014","unstructured":"Said, H. S. et al. Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunological biomarkers. DNA Res 21, 15\u201325 (2014).","journal-title":"DNA Res"},{"key":"23870_CR27","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1126\/science.aan4526","volume":"358","author":"K Atarashi","year":"2017","unstructured":"Atarashi, K. et al. Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. Science 358, 359\u2013365 (2017).","journal-title":"Science"},{"key":"23870_CR28","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/gutjnl-2011-300784","volume":"61","author":"JJ Farrell","year":"2012","unstructured":"Farrell, J. J. et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut 61, 582\u2013588 (2012).","journal-title":"Gut"},{"key":"23870_CR29","doi-asserted-by":"publisher","first-page":"e1373","DOI":"10.7717\/peerj.1373","volume":"3","author":"PJ Torres","year":"2015","unstructured":"Torres, P. J. et al. Characterization of the salivary microbiome in patients with pancreatic cancer. PeerJ 3, e1373, https:\/\/doi.org\/10.7717\/peerj.1373 (2015).","journal-title":"PeerJ"},{"key":"23870_CR30","first-page":"3111","volume":"5","author":"X Yan","year":"2015","unstructured":"Yan, X. et al. Discovery and validation of potential bacterial biomarkers for lung cancer. Am J Cancer Res 5, 3111\u20133122 (2015).","journal-title":"Am J Cancer Res"},{"key":"23870_CR31","doi-asserted-by":"publisher","unstructured":"Flemer, B. et al. The oral microbiota in colorectal cancer is distinctive and predictive. Gut, https:\/\/doi.org\/10.1136\/gutjnl-2017-314814 (2017).","DOI":"10.1136\/gutjnl-2017-314814"},{"key":"23870_CR32","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00248-015-0592-9","volume":"70","author":"M Piccolo","year":"2015","unstructured":"Piccolo, M. et al. Salivary microbiota associated with immunoglobulin A nephropathy. Microb Ecol 70, 557\u2013565 (2015).","journal-title":"Microb Ecol"},{"key":"23870_CR33","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1128\/AEM.00362-14","volume":"80","author":"R Francavilla","year":"2014","unstructured":"Francavilla, R. et al. Salivary microbiota and metabolome associated with celiac disease. Appl Environ Microbiol. 80, 3416\u20133425 (2014).","journal-title":"Appl Environ Microbiol."},{"key":"23870_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.clim.2016.06.002","volume":"169","author":"P Coit","year":"2016","unstructured":"Coit, P. et al. Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behcet\u2019s disease. Clin Immunol 169, 28\u201335 (2016).","journal-title":"Clin Immunol"},{"key":"23870_CR35","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/nm.3914","volume":"21","author":"X Zhang","year":"2015","unstructured":"Zhang, X. et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med 21, 895\u2013905 (2015).","journal-title":"Nat Med"},{"key":"23870_CR36","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nature13178","volume":"509","author":"T Ding","year":"2014","unstructured":"Ding, T. & Schloss, P. D. Dynamics and associations of microbial community types across the human body. Nature 509, 357\u2013360 (2014).","journal-title":"Nature"},{"key":"23870_CR37","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/MPG.0000000000000239","volume":"58","author":"A Levine","year":"2014","unstructured":"Levine, A. et al. ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 58, 795\u2013806 (2014).","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"23870_CR38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1093\/dnares\/dst006","volume":"20","author":"SW Kim","year":"2013","unstructured":"Kim, S. W. et al. Robustness of gut microbiota of healthy adults in response to probiotic intervention revealed by high-throughput pyrosequencing. DNA Res 20, 241\u2013253 (2013).","journal-title":"DNA Res"},{"key":"23870_CR39","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.1128\/AEM.67.9.4374-4376.2001","volume":"67","author":"DR Singleton","year":"2001","unstructured":"Singleton, D. R., Furlong, M. A., Rathbun, S. L. & Whitman, W. B. Quantitative comparisons of 16S rRNA gene sequence libraries from environmental samples. Appl Environ Microbiol 67, 4374\u20134376 (2001).","journal-title":"Appl Environ Microbiol"},{"key":"23870_CR40","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/biomet\/40.3-4.237","volume":"40","author":"IJ Good","year":"1953","unstructured":"Good, I. J. The population frequencies of species and the estimation of population parameters. Biometrika 40, 237\u2013264 (1953).","journal-title":"Biometrika"},{"key":"23870_CR41","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000330778","volume":"72","author":"ML Calle","year":"2011","unstructured":"Calle, M. L., Urrea, V., Boulesteix, A. L. & Malats, N. AUC-RF: A new strategy for genomic profiling with random forest. Hum Hered 72, 121\u2013132 (2011).","journal-title":"Hum Hered"},{"key":"23870_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/srep33142","volume":"6","author":"H Lu","year":"2016","unstructured":"Lu, H. et al. Deep sequencing reveals microbiota dysbiosis of tongue coat in patients with liver carcinoma. Sci Rep 6, 33142, https:\/\/doi.org\/10.1038\/srep33142 (2016).","journal-title":"Sci Rep"},{"key":"23870_CR43","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1002\/hep.24570","volume":"54","author":"N Razumilava","year":"2011","unstructured":"Razumilava, N., Gores, G. J. & Lindor, K. D. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 54, 1842\u20131852 (2011).","journal-title":"Hepatology"},{"key":"23870_CR44","doi-asserted-by":"publisher","unstructured":"Takayasu, L. et al. Circadian oscillations of microbial and functional composition in the human salivary microbiome. DNA Res, https:\/\/doi.org\/10.1093\/dnares\/dsx001 (2017).","DOI":"10.1093\/dnares\/dsx001"},{"key":"23870_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/srep22164","volume":"6","author":"T Takeshita","year":"2016","unstructured":"Takeshita, T. et al. Bacterial diversity in saliva and oral health-related conditions: The Hisayama Study. Sci Rep 6, 22164, https:\/\/doi.org\/10.1038\/srep22164 (2016).","journal-title":"Sci Rep"},{"key":"23870_CR46","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s00535-005-1758-x","volume":"41","author":"S Tada","year":"2006","unstructured":"Tada, S., Ebinuma, H., Saito, H. & Hibi, T. Therapeutic benefit of sulfasalazine for patients with primary sclerosing cholangitis. J Gastroenterol 41, 388\u2013389 (2006).","journal-title":"J Gastroenterol"},{"key":"23870_CR47","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/j.1440-1746.1998.tb00740.x","volume":"13","author":"K Kozaiwa","year":"1998","unstructured":"Kozaiwa, K. et al. Three paediatric cases of primary sclerosing cholangitis treated with ursodeoxycholic acid and sulphasalazine. J Gastroenterol Hepatol 13, 825\u2013829 (1998).","journal-title":"J Gastroenterol Hepatol"},{"key":"23870_CR48","doi-asserted-by":"publisher","first-page":"e01693","DOI":"10.1128\/mBio.01693-15","volume":"6","author":"E Zaura","year":"2015","unstructured":"Zaura, E. et al. Same exposure but two radically different responses to antibiotics: Resilience of the salivary microbiome versus long-term microbial shifts in feces. MBio 6, e01693\u201301615, https:\/\/doi.org\/10.1128\/mBio.01693-15 (2015).","journal-title":"MBio"},{"key":"23870_CR49","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1264\/jsme2.22.214","volume":"22","author":"H Morita","year":"2007","unstructured":"Morita, H. et al. An improved DNA isolation method for metagenomic analysis of the microbial flora of the human intestine. Microbes Environ 22, 214\u2013222 (2007).","journal-title":"Microbes Environ"},{"key":"23870_CR50","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/ismej.2010.133","volume":"5","author":"C Lozupone","year":"2011","unstructured":"Lozupone, C., Lladser, M. E., Knights, D., Stombaugh, J. & Knight, R. UniFrac: An effective distance metric for microbial community comparison. ISME J 5, 169\u2013172 (2011).","journal-title":"ISME J"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23870-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23870-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23870-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T04:01:24Z","timestamp":1671595284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-23870-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,3]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["23870"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-23870-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,3]]},"assertion":[{"value":"11 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5480"}}